BIO5192 hydrate

98%

Powder: -20 degree C for 3 years
In solvent: -80 degree C for 2 years

<1mg/ml refers to the product slightly soluble or insoluble

The combination of BIO5192 hydrate (1 mg/kg; i.v.) and Plerixafor (5 mg/kg; s.c.) exert an additive effect on progenitor mobilization[1].BIO5192 hydrate (30 mg/kg; s.c; bid; during days 5 through 14) delays paralysis associated with EAE (experimental autoimmune encephalomyelitis)[2].BIO5192 hydrate (1 mg/kg, i.v.) shows the terminal half-life is 1.1 hours. BIO5192 hydrate (3, 10, and 30 mg/kg; s.c.) shows half-lives of 1.7, 2.7, and 4.7 hours, respectively. The blood plasma curves show that the AUC for the s.c. route of administration increased about 2.5-fold from 5,460 h/ng/mL for the 3mg/kg dose to 14,175 h/ng/mL for the 30 mg/kg[1]. Animal Model: C57BL/6J x 129Sv/J F1 mice[1]